Core Viewpoint - The investment strategy for the medical device sector in 2026 will focus on overseas expansion and innovation, emphasizing companies with strong product innovation capabilities and those that have mitigated domestic market price pressures [1] Group 1: Investment Focus Areas - Emphasis on leading companies in the digestive endoscope consumables sector that are expanding into mature overseas markets and are beginning to see the bottoming out of domestic procurement impacts [1] - Attention to home medical device leaders with strong domestic brand power and innovative wearable products that are accelerating their expansion into overseas markets [1] - Focus on Hong Kong-listed medical device companies that are innovating with differentiated products in the cardiovascular intervention field [1]

Group 1 - The core investment strategy for 2026 will focus on overseas expansion and innovation, targeting high-quality medical device companies with strong product innovation capabilities and reduced domestic market price pressures [1][2] - Key companies to watch include Nanwei Medical (688029.SH) for its leadership in overseas mature market expansion and gradual recovery from domestic procurement impacts, Yuyue Medical (002223.SZ) for its strong domestic brand and innovation in wearable devices, and Xianjian Technology (01302) for its differentiated innovation in cardiovascular intervention products [1][2] - In 2025, policy support was clear, leading to increased market share for leading companies despite weak domestic demand and price adjustments [1][2] Group 2 - The focus on overseas markets is expected to provide additional growth opportunities, while innovative products will support profit margins during periods of price decline in traditional businesses [2][3] - The medical device sector's growth will increasingly depend on domestic manufacturers' technological breakthroughs, overseas expansion, and the continuous growth of grassroots healthcare markets [3] - The high-value consumables market will see ongoing policy developments, with an emphasis on international expansion, particularly in Europe and the United States, where previous investments in overseas channels and production bases are expected to yield accelerated growth in 2026 [3][4] Group 3 - In vitro diagnostics are experiencing a market contraction due to centralized procurement, but leading domestic companies are gaining market share through pricing and channel advantages, accelerating import substitution [4] - The internationalization of domestic home medical device companies is a core strategy, with major players leveraging acquisitions and overseas product registrations to expedite their market entry [4] - By 2026, some companies are expected to enter a growth phase in overseas markets and innovative products, particularly in respiratory therapy and blood glucose management [4]